Fosamax, a medication manufactured by Merck, is typically prescribed to treat osteoporosis and other bone-related conditions.  Long-term Fosamax use has been linked to osteonecrosis of the jaw (“ONJ”), and femur fractures.  The Fosamax lawyers at Bernstein Liebhard LLP believe that the makers of Fosamax should be held accountable for failing to properly warn consumers of the severe and dangerous side effects associated with Fosamax use.  If you or a loved one used Fosamax and sustained a femur fracture, you may want to contact a Fosamax lawyer for a free case evaluation.

Osteoporosis And Fosamax

Fosamax is commonly prescribed to postmenopausal women in order to strengthen bones and reduce the propensity of fractures.  Ironically, Fosamax, a drug used to treat patients with osteoporosis, has caused the very same patients to suffer atypical femur fractures, especially after long-term use of the drug.  Given that the femur is one of the strongest bones in the body, it is one of the hardest to fracture.  Unfortunately, patients who suffer a femur fracture are likely to experience a reduced quality of life.  If you took Fosamax and sustained an atypical femur fracture, you may be entitled to seek compensation for your injuries.  The Fosamax lawyers at Bernstein Liebhard LLP believe that Merck failed to warn consumers of the risks associated with the drug, that the defective design of the drug makes it unsafe, and that the manufacturer breached implied and expressed warranties.

How A Fosamax Lawyer Can Help You

With the assistance of a Fosamax lawyer from Bernstein Liebhard LLP, patients who were injured as a result of taking Fosamax can initiate a lawsuit against Merck seeking compensation for their injuries.  The Fosamax lawyers at our firm believe that Merck knew that Fosamax put patients at an increased risk for femur fractures, yet failed to adequately warn consumers.  If you took Fosamax and sustained a femur fracture, a Fosamax lawyer may be able to help you collect compensation for expenses related to your injuries, including:

  • medical bills
  • pain and suffering
  • lost income
  • permanent disability costs
  • out-of-pocket expenses

Fosamax Lawyers Will Protect Your Legal Rights

The Fosamax lawyers at our firm believe that Merck’s failure to adequately warn patients about the serious and debilitating side effects associated with the drug gives rise to a legal claim by those who were injured while or after taking the drug.  Merck received approval by the U.S. Food and Drug Administration (“FDA”) in 1995 without having performed any long-term safety testing.  In March 2010, faced with increasing complaints, the FDA announced an ongoing safety review of Fosamax and its relationship to atypical femur fractures.  In October 2010, the FDA required Merck to advise patients about the possible risk of atypical femur fractures.  Given the increased media attention and heightened FDA scrutiny, our Fosamax lawyers expect the number of Fosamax lawsuits to dramatically increase.

The Fosamax lawyers at Bernstein Liebhard LLP are actively filing cases on behalf of clients who were injured as a result of taking Fosamax.  These individual lawsuits have been consolidated into a mass tort action, which is pending before the Honorable Carol E. Higbee in New Jersey state court.  In addition, our team of Fosamax lawyers has spoken to hundreds of women about their injuries and understands the serious complications that can result from a femur fracture.  If you sustained an atypical femur fracture, our Fosamax lawyers will answer your questions and try to alleviate your concerns in a caring and sympathetic manner.

Contact A Fosamax Lawyer Today

Speak with one of our Fosamax lawyers for a free case evaluation.  Our Fosamax lawyers operate on a contingency fee basis, which means you pay no fees or charges up front. In fact, you pay nothing unless a Fosamax lawyer can achieve a favorable outcome in your case.  We handle cases nationwide.

To learn more about your legal rights, contact a Fosamax lawyer at our firm today.

Published November 17, 2011 by